Regenerative Medicine Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Type (Stem Cell Therapy, Gene Therapy, Tissue Engineering, Small Molecules & Biologics), By Application (Cardiovascular, Oncology, Dermatology, Musculoskeletal, Others), By End-User (Hospitals, Biomedical Laboratories, Research Centers), And By Geography - Forecasts From 2022 To 2027

  • Published : Jan 2023
  • Report Code : KSI061611493
  • Pages : 139

The regenerative medicine market is estimated to be valued at US$19.322 billion in 2020.

Regenerative treatments or medicines work inside to repair damaged bodily tissues or organs. These medications fix the injured body organs that would otherwise be unable to mend naturally—a process known as rejuvenation. Regenerative medicines can also be used to replace damaged cells, tissues, or organs by using healthy cells, tissues, or organs from a deceased or healthy donor. The second method of using these medications to repair damaged tissue involves transferring healthy cells or tissues to sick or injured cells in order to maintain the body's regular functioning, a process known as regeneration.

Increasing rates of hereditary disorders and chronic diseases to boost the market

The demand for cell therapy in the regenerative medicine industry is rising due to the rise in disorders including Duchenne muscular dystrophy (DMD), Parkinson's disease, congestive heart failure, and myocardial infarction. Additionally, the market expansion is driven by the use of heterotopic autologous grafts, such as intestine, colon, or stomach, for the reconstruction of the bladder, ureter, and urethra. Many businesses are working with other businesses or research institutions in an effort to advance cell therapy. Government funding for regenerative medicine research is expected to increase, which is one of the main factors driving market expansion. Additionally, a rising pipeline of regenerative medicine treatments and an increase in product approvals will further fuel market expansion potential in the years to come.

By Geography

Geographically, the Regenerative medicines market is segmented as North America, South America, Europe, the Middle East and Africa, and Asia Pacific. The greatest market share corresponds to the North American region owing to the expansion of the healthcare sector and the rising adoption of stem cell therapy.

Key Developments:

  • June 2022: The PERLA phase II trial fulfilled its primary endpoint of the objective response rate (ORR) using Response Evaluation Criteria in Solid Tumors (RECIST) criteria as evaluated by a blinded independent central review, according to the headline results released by GSK plc. In first-line patients with metastatic non-squamous non-small cell lung cancer, the trial compared dostarlimab in combination with chemotherapy to pembrolizumab in combination with chemotherapy (NSCLC). The PERLA phase II trial, the largest global head-to-head trial of programmed death receptor-1 (PD-1) inhibitors in this cohort, is a randomized, double-blind experiment involving 243 patients. Additionally, GSK is moving the COSTAR Lung trial's two arms into phase III. Given that the trial complied with the Independent Data Monitoring Committee's protocol-required expansion criteria, the decision is made in accordance with their advice. The COSTAR Lung phase III trial is a randomized, open-label, three-arm study in patients with advanced NSCLC who have progressed on prior anti-PD-(L)1 therapy and chemotherapy. It compares cobolimab, an investigational selective anti-TIM-3 monoclonal antibody, plus dostarlimab plus docetaxel to dostarlimab plus docetaxel to docetaxel alone.
  • Dec 2021: In order to inhibit a target identified at the Novartis Institutes for BioMedical Research, Novartis and Alnylam announced a collaboration. This partnership could result in the creation of a therapy that encourages the growth of functional liver cells and offers liver failure patients an alternative to transplantation. The company has developed a restorative technique that may provide patients with liver failure with a revolutionary benefit, building on its history as a leader in regenerative medicine. Additionally, the company desires to work with Alnylam in this new partnership since Alnylam's siRNA platform is the best choice for converting this idea into a clinical study. Alnylam will create and test prospective siRNAs using target-specific assays created by Novartis during the three-year research partnership. Novartis will carry out additional development and clinical studies after a lead candidate has been found.

Product Offerings:

  • BLENREP: For patients whose disease has advanced despite earlier treatment with an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody, BLENREP is a first-in-class anti-BCMA (B-cell maturation antigen) therapy. BLENREP is GSK's seventh significant medication to be approved in 2020. Adult patients with relapsed or resistant multiple myeloma who have had at least four prior therapies, such as an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory drug, can receive BLENREP (belantamab mafodotin-blmf) as a monotherapy. Based on the response rate, this indication is authorized under accelerated approval. The confirmation and description of clinical benefits in confirmatory trials may be a requirement for the continuation of authorization for this indication. The anti-BCMA (B-cell maturation antigen) medication BLENREP is the first of its kind to receive worldwide approval.
  • ZYNTEGLO: For patients with beta-thalassemia, commonly known as beta-thalassemia major or Cooley's anaemia, who require frequent transfusions, ZYNTEGLO is a once-only gene therapy. A mutation in the beta-globin gene, which results in the body producing little or no beta-globin, is the cause of beta-thalassemia. Each patient receives a unique formulation of ZYNTEGLO that incorporates functioning beta-globin gene copies into their own blood stem cells. The patient may be able to manufacture enough hemoglobin, as a result, to stop needing frequent transfusions.

Regenerative Medicine Market Scope:


Report Metric Details
 Market Size Value in 2020  US$19.322 billion
 Growth Rate  CAGR during the forecast period
 Base Year  2020
 Forecast Period  2022–2027
 Forecast Unit (Value)  USD Billion
 Segments Covered  Type, Application, End User, And Geography
 Regions Covered  North America, South America, Europe, Middle East and Africa, Asia Pacific
 Companies Covered Novartis, Amgen, Bluebird Bio, GSK plc., Shenzhen Sibiono Genetech, Anterogen CO., LTD., Chiesi Farmaceutici S.p.a., Jcr Pharmaceuticals, Nipro
 Customization Scope  Free report customization with purchase



  • By Type
    • Stem cell Therapy
    • Gene Therapy
    • Tissue Engineering
    • Small Molecules & Biologics
  • By Application
    • Cardiovascular
    • Oncology
    • Dermatology
    • Musculoskeletal
    • Others
  • By End user
    • Hospitals
    • Biomedical laboratories
    • Research centers
  • By Geography
    • North America
      • USA
      • Mexico
      • Canada
    • South America
      • Brazil
      • Argentina
      • Others
    • Europe
      • Germany
      • France
      • United Kingdom
      • Italy
      • Others
    • Middle East and Africa
      • Saudi Arabia
      • UAE
      • Israel
      • Others
    • Asia Pacific
      • India
      • China
      • Japan
      • South Korea
      • Taiwan
      • Thailand
      • Indonesia
      • Others

Frequently Asked Questions (FAQs)

Regenerative Medicine Market was valued at US$19.322 billion in 2020.
Prominent key market players in the regenerative medicine market include Novartis, Amgen, Bluebird Bio, GSK plc., Shenzhen Sibiono Genetech, and Anterogen CO., LTD., among others.
The global regenerative medicine market has been segmented by type, application, end-user, and geography.
Increasing rates of hereditary disorders and chronic diseases are major factors to boost the regenerative medicine market growth.
North America holds the largest share of the regenerative medicine market owing to the expansion of the healthcare sector and the rising adoption of stem cell therapy.


1.1. Market Overview

1.2. COVID-19 Scenario

1.3. Market Definition

1.4. Market Segmentation



2.1. Research Data

2.2. Assumptions



3.1. Research Highlights



4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Forces Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis



5.1. Introduction

5.2. Stem Cell Therapy

5.3. Tissue Engineering

5.4. Small Molecules & Biologics



6.1. Introduction

6.2. Cardiovascular

6.3. Oncology

6.4. Dermatology

6.5. Musculoskeletal

6.6. Others



7.1. Hospitals

7.2. Biomedical Laboratories

7.3. Research centers



8.1. Introduction

8.2. North America

8.2.1. USA

8.2.2. Canada

8.2.3. Mexico

8.3. South America

8.3.1. Brazil

8.3.2. Argentina

8.3.3. Others

8.4. Europe

8.4.1. Germany

8.4.2. France

8.4.3. United Kingdom

8.4.4. Italy

8.4.5. Others

8.5. Middle East and Africa

8.5.1. Saudi Arabia

8.5.2. UAE

8.5.3. Israel

8.5.4. Others

8.6. Asia Pacific

8.6.1. China

8.6.2. Japan

8.6.3. India

8.6.4. South Korea

8.6.5. Taiwan

8.6.6. Thailand

8.6.7. Indonesia

8.6.8. Others



9.1. Major Players and Strategy Analysis

9.2. Emerging Players and Market Lucrativeness

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Vendor Competitiveness Matrix



10.1. Novartis

10.2.  Amgen

10.3.  Bluebird Bio

10.4. GSK plc.

10.5.  Sibiono Genetech

10.6. Anterogen Co. Limited

10.7. Chiesi Farmaceutici S.p.a.

10.8. Jcr Pharmaceuticals 

10.9. Nipro 



Bluebird Bio

GSK plc.

Shenzhen Sibiono Genetech

Anterogen CO., LTD.

Chiesi Farmaceutici S.p.a.

Jcr Pharmaceuticals